Advertisement
Research Article

Soluble Rhesus Lymphocryptovirus gp350 Protects against Infection and Reduces Viral Loads in Animals that Become Infected with Virus after Challenge

  • Junji Sashihara,

    Affiliation: Medical Virology Section, Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, United States of America

    Current address: Department of Pediatrics, Kansai Rousai Hospital, Hyogo, Japan.

    X
  • Yo Hoshino,

    Affiliation: Medical Virology Section, Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, United States of America

    Current address: Astellas Pharma Inc., Tokyo, Japan.

    X
  • J. Jason Bowman,

    Affiliation: Medical Virology Section, Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, United States of America

    X
  • Tammy Krogmann,

    Affiliation: Medical Virology Section, Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, United States of America

    X
  • Peter D. Burbelo,

    Affiliation: Neurobiology and Pain Therapeutics Section, Laboratory of Sensory Biology, National Institute of Dental and Craniofacial Research, National Institutes of Health, Bethesda, Maryland, United States of America

    X
  • V. McNeil Coffield,

    Affiliation: AlphaVax, Inc., Research Triangle Park, North Carolina, United States of America

    Current address: Department of Biology, High Point University, High Point, North Carolina, United States of America.

    X
  • Kurt Kamrud,

    Affiliation: AlphaVax, Inc., Research Triangle Park, North Carolina, United States of America

    Current address: Harrisvaccines, Inc. Ames, Iowa, United States of America.

    X
  • Jeffrey I. Cohen mail

    jcohen@niaid.nih.gov

    Affiliation: Medical Virology Section, Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, United States of America

    X
  • Published: October 20, 2011
  • DOI: 10.1371/journal.ppat.1002308

About the Authors

Junji Sashihara, Yo Hoshino, J. Jason Bowman, Tammy Krogmann, Jeffrey I. Cohen
Medical Virology Section, Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, United States of America
Peter D. Burbelo
Neurobiology and Pain Therapeutics Section, Laboratory of Sensory Biology, National Institute of Dental and Craniofacial Research, National Institutes of Health, Bethesda, Maryland, United States of America
V. McNeil Coffield, Kurt Kamrud
AlphaVax, Inc., Research Triangle Park, North Carolina, United States of America

Corresponding Author

Email: jcohen@niaid.nih.gov

Competing Interests

The authors have declared that no competing interests exist.

Author Contributions

Conceived and designed the experiments: JIC. Performed the experiments: JS YH JJB TK PDB VMC KK. Analyzed the data: JS YH JJB PDB VMC KK JIC. Wrote the paper: JIC.